ArticleThe American journal of case reports2023

Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.

Jie Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.